On February 13, 2020, Guerin, David J.; Ng, Pui Yee; Wang, Zhongguo; Shelekhin, Tatiana; Caravella, Justin; Zablocki, Mary-Margaret; Downing, Jennifer R.; Li, Hongbin; Ioannidis, Stephanos published a patent.Related Products of 227940-70-7 The title of the patent was Preparation of carboxamides as ubiquitin-specific protease inhibitors. And the patent contained the following:
The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The title compounds I [Y = C(R3) and N; R’ = H and Me; R1 = (un)substituted 6-11 membered heteroaryl; R2 = (un)substituted N-linked 4-12 membered heterocyclyl and C-linked 4-12 membered heterocyclyl; each R3 = (independently) H, D, alkyl, alkoxy, etc.; R4 = H, D, alkyl, halo, etc.; n = 0-3; with the proviso] or pharmaceutically acceptable forms thereof, useful as modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, and can be useful in the treatment of cancers, among other ailments, were prepared and/or claimed. E.g., a multi-step synthesis of (R)-II and (S)-II, starting from 4-bromo-2-hydroxybenzaldehyde and acrylonitrile, was described. Exemplified compounds I were tested for their USP28 and USP25 activities (data given for representative compounds I). Pharmaceutical composition comprising compound I was claimed. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).Related Products of 227940-70-7
The Article related to carboxamide heteroaryl preparation ubiquitin specific protease inhibitor usp28 usp25, antitumor usp28 usp25 inhibitor carboxamide amide heteroaryl preparation, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Related Products of 227940-70-7
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics